Phase 3 N=5 Liraglutide in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Mean Weekly Blood Glucose — 187; 178 mg/dL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=242 Study to Compare the Efficacy and Safety of F-627 and GRAN®
Breast Cancer · Neutropenia
Primary: Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1 — 0.68; 0.71 days
Phase 3 N=207 Efficacy and Safety of Inclisiran as Monotherapy in Chinese Adults With Low or Moderate ASCVD Risk and Elevated Low-density Lipoprotein Cholesterol.
Primary Hypercholesterolemia or Mixed Dyslipidemia
Primary: Percentage Change in Low-density Lipoprotein Cholesterol (LDL-C) (mg/dL) From Baseline at Day 150 - Core Analysis: Core Part — -45.87; 1.62 % change in LDL-C — p=<0.0001
Phase 3 N=20 Effect of Ensifentrine Treatment on CAT Score
COPD
Primary: The Proportion of CAT Score Responders in the Full Analysis Set at Week 12 — 12 Participants
Phase 3 N=594 Safety and Tolerability of Intravenous VIT-45 in Patients With Iron Deficiency Anemia
Anemia
Primary: Incidence of Treatment-emergent Adverse Events During Each 7-day Study Period — 174; 114 participants
Phase 3 N=162 Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Actinic Keratosis · Warts · Basal Cell Carcinoma
Primary: Number of Accumulated New Skin Lesions at Month 3 — 65; 103 new skin lesions — p=0.0120
Phase 3 N=165 A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Generalized Myasthenia Gravis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 78.4; 94.1 percentage of participants
Phase 3 N=166 A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation
Chronic Lymphocytic Leukemia (CLL)
Primary: Minimal Residual Disease (MRD) Response Rate Measured in Peripheral Blood (PB) Using Next Generation Sequencing (NGS) — 81.3; 54.7 percentage of participants — p=0.0004
Phase 3 N=185 Comparing Internet and In-Person Brief Cognitive Behavioral Therapy of Insomnia
Insomnia
Primary: Sleep Diary Sleep Efficiency — 73.2; 72.5; 72.9; 84.5 Percentage Total Sleep Time/Time in Bed
Phase 3 N=6 Evaluating the Clinical Accuracy of Gallium-68 PSMA PET/CT Imaging in Patients With Biochemical Recurrence of Prostate Cancer
Prostatic Neoplasms · Prostatic Neoplasms, Castration-Resistant
Primary: Sensitivity of Ga 68-labeled PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) for the Detection on a Per Patient Basis — 1.0 proportion of participants
Phase 3 N=304 AScalate: Treat-to-target in Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Percentage of Patients Achieving an ASAS40 Response at Week 24 — 40.1; 49.2 Percentage of participants — p=0.119
Phase 3 N=235 A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
Migraine
Primary: Mean Change From Baseline in Monthly Average Number of Migraine Days During 12-Week Period After the First Dose of Study Drug — -1.4; -2.5 days/month — p=0.0210
Phase 3 N=61 Clinical Trial to Evaluate the Effect of Raltegravir Intensification (1.200 mg QD) on the Gut Microbiota of Chronically HIV-1 Infected Subject Over Time: THE RAGTIME STUDY
HIV
Primary: Bacterial Gene Richness (Observed Unique Genes). Analysis of the Composition, Structure and Function of the Intestinal Microbiome. * — 768358; 730732; 767756; 808911…
Phase 3 N=1,085 A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
Multiple Myeloma
Primary: Post-Consolidation Stringent Complete Response (sCR) Rate — 110; 157 Participants — p=0.0010
Phase 3 N=481 An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients With Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 — 478 Participants